AdvisorShares Investments LLC Acquires 12,869 Shares of Supernus Pharmaceuticals, Inc. $SUPN

AdvisorShares Investments LLC boosted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 82.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,394 shares of the specialty pharmaceutical company’s stock after acquiring an additional 12,869 shares during the period. AdvisorShares Investments LLC’s holdings in Supernus Pharmaceuticals were worth $1,411,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. boosted its holdings in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 281 shares in the last quarter. Torren Management LLC acquired a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $49,000. EverSource Wealth Advisors LLC acquired a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $51,000. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $55,000.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $46.18 on Friday. The firm has a fifty day moving average of $49.69 and a two-hundred day moving average of $49.56. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of -90.55, a PEG ratio of 1.01 and a beta of 0.57. Supernus Pharmaceuticals, Inc. has a 52 week low of $30.83 and a 52 week high of $59.68.

Insider Activity

In related news, CEO Jack A. Khattar sold 35,000 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the completion of the sale, the chief executive officer owned 958,100 shares in the company, valued at $48,259,497. This represents a 3.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Georges Gemayel sold 8,787 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00. Following the completion of the sale, the director owned 27,277 shares of the company’s stock, valued at approximately $1,445,681. This represents a 24.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 116,406 shares of company stock worth $5,911,086 in the last 90 days. Corporate insiders own 8.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SUPN. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Finally, Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.